Listen to a preview of Drugs, Devices or Data - Which is Most Valuable? Webcast

Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.

The EVERSANA team discusses its new technology center that has a goal of pharmatizing AI.

Alliance Pharmaceuticals plans to use the new to attack counterfeiters rather than just defend against them.

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.